Bortezomib (Velcade™) in the Treatment of Multiple Myeloma

References

• AdamsJPalombellaVJSausvilleEAProteasome inhibitors: a novel class of potent and effective antitumor agentsCancer Res19995926152210363983
   PubMed Web of Science ®Google Scholar
• AdamsJThe proteasome: a suitable antineoplastic targetNat Rev Cancer200443496015122206
   PubMed Web of Science ®Google Scholar
• AghajanianCSoignetSDizonDSA phase I trial of the novel proteasome inhibitor PS341 in advanced and solid tumor malignanciesClin Cancer Res2002825051112171876
   PubMed Web of Science ®Google Scholar
• AlexanianRWangLWeberDVTD (Velcade, Thalidomide, Dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]Blood2004104210
   Web of Science ®Google Scholar
• AlvaresCDaviesFHortonCLong-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatmentsBr J Haematol20051296071415916682
   PubMed Web of Science ®Google Scholar
• BerensonJYangHSadlerKPhase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJ Clin Oncol2006249374416418495
   PubMed Web of Science ®Google Scholar
• BladeJSamsonDReeceDCriteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantationBr J Haematol19981021115239753033
   PubMed Web of Science ®Google Scholar
• CavoMZamagniETosiPSuperiority of thalidomide and dexamethasone over vincristine doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood200510635915761019
   PubMed Web of Science ®Google Scholar
• Chanan-KhanARichardsonPLonialSSafety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis [abstract]Blood20051062550
   Web of Science ®Google Scholar
• [EMEA] European Medicines AgencyEuropean public assessment report: scientific discussion. The committee for medicinal products for human use [online]2004 Accessed 20 March 2006 URL: http://www.emea.eu.int/humandocs/Humans/EPAR/velcade/velcade.htm
   Google Scholar
• FaconTMaryJYPegourieBDexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyBlood20061071292816174762
   PubMed Web of Science ®Google Scholar
• GoyAYounesAMcLaughlinPPhase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaJ Clin Oncol2005236677515613697
   PubMed Web of Science ®Google Scholar
• HarousseauJ-LAttalMLeleuXBortezomib (Velcade) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]Blood2004104149015155458
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPChauhanDThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsCancer Res2001613071611306489
   PubMed Web of Science ®Google Scholar
• HideshimaTMitsiadesCAkiyamaMMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood20031011530412393500
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJA phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBr J Haematol20041271657215461622
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJRBortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal functionCancer2005103119520015690325
   PubMed Web of Science ®Google Scholar
• JagannathSDurieBWoldJBortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma [abstract]Blood2005106783
   Web of Science ®Google Scholar
• KarinMCaoYGretenFRNF-kappa in cancer: from innocent bystander to major culpritNat Rev Cancer200223011012001991
   PubMed Web of Science ®Google Scholar
• KropffMBispingGLiebischPBortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma [abstract]Blood20051062549
   Web of Science ®Google Scholar
• LandowskiTHMegliCJNullmeyerKDMitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell linesCancer Res20056538283615867381
   PubMed Web of Science ®Google Scholar
• LeBlancRCatleyLPHideshimaTProteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelCancer Res2002624996500012208752
   PubMed Web of Science ®Google Scholar
• LonialSWallerEKRichardsonPGRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood200510637778416099887
   PubMed Web of Science ®Google Scholar
• LudwigHKhayatDGiacconeGProteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignanciesCancer2005104179480716178003
   PubMed Web of Science ®Google Scholar
• MaMHYangHHParkerKThe proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsClin Cancer Res2003911364412631619
   PubMed Web of Science ®Google Scholar
• MateosMVHernándezMMediavillaJDA phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma (MM) patients [abstract]Blood2005106786
   Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGThe proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood200310123778012424198
   PubMed Web of Science ®Google Scholar
• [NCI] National Cancer InstituteCommon terminology criteria for adverse events v3.0 [online]2003 Accessed 12 October 2005 URL: http://ctep.cancer.gov/forms/CTCAEv3.pdf
   Google Scholar
• OakerveeHPopatRCurryNPAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBr J Haematol20051297556215953001
   PubMed Web of Science ®Google Scholar
• OrlowskiRZStinchcombeTEMitchellBSPhase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesJ Clin Oncol2002204420712431963
   PubMed Web of Science ®Google Scholar
• OrlowskiRZVoorheesPMGarciaRAPhase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood200510530586515626743
   PubMed Web of Science ®Google Scholar
• PalumboAAmbrosiniMTPregnoPVelcade plus melphalan, prednisolone, and thalidomide for advanced multiple myeloma [abstract]Blood20051062553
   Web of Science ®Google Scholar
• PopatROakerveeHEFootNA Phase I/II study of bortezomib and low dose intravenous melphalan for relapsed myeloma [abstract]Blood20051062555
   Web of Science ®Google Scholar
• RajkumarSVRichardsonPHideshimaTProteasome inhibition as a novel therapeutic target in human cancerJ Clin Oncol200523630915659509
   PubMed Web of Science ®Google Scholar
• ReeceDEPizaGRTrudelSA phase I-II trial of bortezomib (Velcade) and oral cyclophosphamide plus prednisolone for relapsed/refractory multiple myeloma [abstract]Blood20051062556
   Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA Phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med200334826091712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPBarlogieBBerensonJClinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaBlood200510629778116020506
   PubMed Web of Science ®Google Scholar
• RichardsonPGBriembergHJagannathSCharacterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE). The SUMMIT and CREST study groupHematol J20045S129
   Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Eng J Med2005a352248798
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib continues to demonstrate superior efficacy compared with high dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial [abstract]Blood2005b1062547
   Web of Science ®Google Scholar
• RichardsonPSchlossmanRMunshiNA phase 1 trial of lenalidomide (Revlimid) with bortezomib (Velcade) in relapsed and refractory multiple myeloma [abstract]Blood2005106365
   Web of Science ®Google Scholar
• RosinolLMontotoSCibeiraMTBortezomib-induced severe hepatitis in multiple myeloma: a case reportArch Intern Med2005165464515738379
   PubMed Web of Science ®Google Scholar
• San MiguelJFRichardsonPSonneveldPFrequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial [abstract]Blood2005106366
   Web of Science ®Google Scholar
• SuvannasankhaASmithGWeekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma [abstract]Blood20051062562
   Web of Science ®Google Scholar
• WangMDelasalleKGiraltSRapid control of previously untreated multiple myeloma with bortezomib-thalidomidedexamethasone followed by early intensive therapy [abstract]Blood2005106784
   Web of Science ®Google Scholar
• ZangariMBarlogieBBurnsMJBortezomib (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II Trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior TBlood20051062552
   Web of Science ®Google Scholar